Gold’s Meteoric Rise: What It Means for Investors and How to Play It Right Gold has been on a blazing hot streak in 2024, surging roughly 35% year-to-date and flirting with the $3,600 per ounce mark—a fresh record that’s capturing the attention of investors across the board. But this isn’t just another shiny headline; it’s…
T. Rowe Price and Goldman Sachs Forge a $1 Billion Alliance: A Game-Changer for Private Market Access In a bold strategic move shaking up the asset management landscape, T. Rowe Price has teamed up with Goldman Sachs in a $1 billion deal aimed at democratizing access to private market investments for retail investors. This partnership,…
Summit Therapeutics Inc. (NASDAQ: SMMT) is rapidly emerging as a compelling growth stock that savvy investors should not overlook—especially in the current biotech landscape where innovation meets strategic partnerships. Recently, H.C. Wainwright boosted its price target for Summit from $44 to $50, reaffirming a Buy rating and signaling strong confidence ahead of Q2 earnings. But…
Bank of America’s recent gold forecast revision is not just another bullish call—it’s a clarion signal for investors to rethink their precious metals strategy amid an increasingly volatile macroeconomic landscape. The bank has raised its average gold price forecast for the next six years by 6%, now projecting a stunning $3,049 per ounce. This isn’t…
Oklo Inc. (NYSE: OKLO) has been turning heads in the nuclear energy sector—and not just among retail investors. The company’s stock has surged an impressive 222% year-to-date, with a remarkable 106% gain since Jim Cramer threw his hat into the ring discussing it earlier this year. Despite Cramer’s cautious and somewhat skeptical take on Oklo,…
Toast, Inc. (NYSE: TOST) is carving out a compelling narrative in the restaurant technology space, and savvy investors should take note. While JP Morgan recently maintained a Neutral rating on the stock, they raised the price target from $42 to $52, signaling an anticipated 19.2% upside from the current price near $43.62. This cautious optimism…
Novo Nordisk’s Bold Move on Ozempic Pricing: What Investors and Advisors Must Know Now Novo Nordisk just shook up the diabetes and obesity drug market with a game-changing pricing strategy for its blockbuster drug Ozempic. As of March 2024, cash-paying U.S. patients can now access Ozempic at less than half the previous monthly list price—$499…
When it comes to hydrogen and industrial gases, Air Products and Chemicals, Inc. (NYSE: APD) stands as a powerhouse that savvy investors cannot afford to overlook. Recently, Citi reaffirmed its Buy rating on APD and even nudged the price target up from $310 to $320 ahead of the company’s Q2 earnings—a move that signals growing…
Energy Prices Take a Sharp Dive—What It Means for Investors Now July brought a notable pullback in energy prices, with a 1.1% decline that provided a much-needed breather for headline inflation numbers. Gasoline prices led the retreat, dropping 2.2% and extending their annual decline to 9.5%. Natural gas also slipped by 0.9%, while electricity costs…
Palantir Technologies Inc. (NASDAQ: PLTR) is carving out a notable position among the best-performing quantum computing stocks in 2025, but investors should look deeper than headline price target upgrades to understand the full picture. On August 4, Citi analyst Tyler Radke raised Palantir’s price target sharply from $115 to $158, reflecting confidence in the company’s…